Loading patent…
AssigneeMedImmune, LLC
InventorsJames F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins
Estimating the term…
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection
A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:
A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO:
A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO:
A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:
A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:
A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:
A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:
A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:
A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.